{
  "symbol": "PAVMZ",
  "company_name": "Pavmed Inc Series Z WT",
  "ir_website": "https://www.pavmed.com/investors/",
  "structured_data": [
    {
      "section_name": "Investors",
      "links": [
        {
          "title": "Investors Homepage",
          "url": "https://ir.pavmed.com",
          "content": "INVESTOR RELATIONS\n\n## Innovation within reach.\n\nInvesting in PAVmed is investing in innovation that has the potential to impact and even transform healthcare. Stay informed about the latest news and updates from our team.\n\n[EMAIL ALERTS](email-alerts)\n\nCOMPANY OVERVIEW\n\nPAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform. Its other subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths.\n\nStock Information\n\nChange\n\nVolume\n\nMarket Cap\n\nStock Information\n\nNASDAQPAVM\n\nLoading...\n\n[Stock Information ](https://ir.pavmed.com/quote)\n\n##  Latest News & Updates\n\n  * News Releases\n  * Events\n\n\n\n[](https://ir.pavmed.com/email-alerts) [Email Alerts](https://ir.pavmed.com/email-alerts)\n\nNov 20, 2024\n\n[Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test](https://ir.pavmed.com/2024-11-20-Lucid-Diagnostics-Submits-Clinical-Evidence-Package-to-MolDX-Seeking-Medicare-Coverage-for-EsoGuard-R-Esophageal-DNA-Test)\n\nLucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...\n\n[Read more](https://ir.pavmed.com/2024-11-20-Lucid-Diagnostics-Submits-Clinical-Evidence-Package-to-MolDX-Seeking-Medicare-Coverage-for-EsoGuard-R-Esophageal-DNA-Test)\n\nNov 18, 2024\n\n[Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum](https://ir.pavmed.com/2024-11-18-Lucid-Diagnostics-to-Present-at-the-Canaccord-Genuity-MedTech,-Diagnostics-and-Digital-Health-Services-Forum)\n\nLucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...\n\n[Read more](https://ir.pavmed.com/2024-11-18-Lucid-Diagnostics-to-Present-at-the-Canaccord-Genuity-MedTech,-Diagnostics-and-Digital-Health-Services-Forum)\n\nNov 14, 2024\n\n[PAVmed Provides Business Update and Third Quarter 2024 Financial Results](https://ir.pavmed.com/2024-11-14-PAVmed-Provides-Business-Update-and-Third-Quarter-2024-Financial-Results)\n\nLucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The...\n\n[Read more](https://ir.pavmed.com/2024-11-14-PAVmed-Provides-Business-Update-and-Third-Quarter-2024-Financial-Results)\n\n[VIEW ALL NEWS](https://ir.pavmed.com/press-releases)\n\n[PAVmed Third Quarter 2024 Business Update](https://ir.pavmed.com/events-and-presentations?item=63)\n\nThursday, November 14, 2024\n\n8:30am - 9:30am EST\n\n[PAVmed Second Quarter 2024 Business Update](https://ir.pavmed.com/events-and-presentations?item=62)\n\nTuesday, August 13, 2024\n\n8:30am - 9:30am EDT\n\n[2024 Annual Meeting of Stockholders](https://ir.pavmed.com/events-and-presentations?item=61)\n\nThursday, June 20, 2024\n\n10:00am EDT\n\n[VIEW ALL EVENTS](https://ir.pavmed.com/events-and-presentations#past)\n\n![](/image/Investors.jpeg)\n\nRESOURCES\n\n![](/image/Investors.jpeg)  \n---  \n  \n  * [Latest Presentation](image/PAVmed+1Q23+Earnings+Webcast+%28FINAL%29+presentation+page.pdf)\n  * [Corporate Overview](index.php?s=45)\n  * [Governance](governance-documents)\n  * [Financials](financial-results)\n  * [Investor Contact](contacts)\n\n\n\n![](images/eyebrow-line-white.svg)\n\n## EMAIL ALERTS\n\nInvestor Updates\n\nInterested in collaborating or looking for more information about our innovations, events, products or partnerships? Connect with us.\n\n[SUBSCRIBE](email-alerts)\n\nEMAIL ALERTS\n\n## Investor Updates\n\n### Email Alerts\n\nSign up for our investor mailing list below to receive the latest news and financials form PAVmed delivered to your inbox.\n\n[SUBSCRIBE](email-alerts)\n"
        }
      ]
    }
  ]
}